{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:45:56Z","timestamp":1787021156862,"version":"build-2736575974"},"reference-count":29,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"33","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO"],"published-print":{"date-parts":[[2024,11,20]]},"abstract":"<jats:p>The FDA's directive to deal with delayed confirmatory trials: lessons from pralatrexate and belinostat for T-cell lymphoma<\/jats:p>","DOI":"10.1200\/jco.24.00100","type":"journal-article","created":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T16:00:49Z","timestamp":1721923249000},"page":"3901-3904","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":7,"title":["US Food and Drug Administration's Directive to Deal With Delayed Confirmatory Trials: Lessons From Pralatrexate and Belinostat for T-Cell Lymphoma"],"prefix":"10.1200","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5977-907X","authenticated-orcid":false,"given":"Edward R. Scheffer","family":"Cliff","sequence":"first","affiliation":[{"name":"Program On Regulation, Therapeutics, And Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, MA"},{"name":"Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1009-2247","authenticated-orcid":false,"given":"David A.","family":"Russler-Germain","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, MO"},{"name":"Siteman Cancer Center, St Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Joseph Ross","family":"Daval","sequence":"additional","affiliation":[{"name":"Program On Regulation, Therapeutics, And Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, MA"},{"name":"Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8867-2666","authenticated-orcid":false,"given":"Aaron S.","family":"Kesselheim","sequence":"additional","affiliation":[{"name":"Program On Regulation, Therapeutics, And Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, MA"},{"name":"Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_7_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/s43441-022-00430-z"},{"key":"e_1_3_7_3_2","article-title":"What clinicians should know about surrogate endpoints in hematologic malignancies","author":"Bommier C","unstructured":"Bommier C, Maurer MJ, Lambert J: What clinicians should know about surrogate endpoints in hematologic malignancies. Blood 10.1182\/blood.2023022269 [epub ahead of print on April 11, 2024]","journal-title":"Blood"},{"key":"e_1_3_7_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.2396"},{"key":"e_1_3_7_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2020.100332"},{"key":"e_1_3_7_6_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n1959"},{"key":"e_1_3_7_7_2","unstructured":"US Food and Drug Administration: November 16 2023: Meeting of the Oncologic Drugs Advisory Committee Meeting Event Materials 2023. https:\/\/www.fda.gov\/advisory-committees\/advisory-committee-calendar\/november-16-2023-meeting-oncologic-drugs-advisory-committee-meeting-announcement-11162023#event-materials"},{"key":"e_1_3_7_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00225"},{"key":"e_1_3_7_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2208954"},{"key":"e_1_3_7_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2104846"},{"key":"e_1_3_7_11_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00889-z"},{"key":"e_1_3_7_12_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.8195"},{"key":"e_1_3_7_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.12.002"},{"key":"e_1_3_7_14_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.9024"},{"key":"e_1_3_7_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.2782"},{"key":"e_1_3_7_16_2","volume-title":"Questioning a $30,000-a-Month Cancer Drug","author":"Pollack A","year":"2009","unstructured":"Pollack A: Questioning a $30,000-a-Month Cancer Drug. The New York Times, 2009"},{"key":"e_1_3_7_17_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.5542"},{"key":"e_1_3_7_18_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2206489"},{"key":"e_1_3_7_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00464-6"},{"key":"e_1_3_7_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00853-z"},{"key":"e_1_3_7_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00821-7"},{"key":"e_1_3_7_22_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01815"},{"key":"e_1_3_7_23_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02658"},{"key":"e_1_3_7_24_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01868"},{"key":"e_1_3_7_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30525-8"},{"key":"e_1_3_7_26_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.186577"},{"key":"e_1_3_7_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2022.12.018"},{"key":"e_1_3_7_28_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02675"},{"key":"e_1_3_7_29_2","volume-title":"Postmarketing Studies and Clinical Trials\u2014Implementation of Section 505(o)(3) of the Federal Food, Drug, and Cosmetic Act Guidance for Industry","author":"US Food and Drug Administration","year":"2011","unstructured":"US Food and Drug Administration: Postmarketing Studies and Clinical Trials\u2014Implementation of Section 505(o)(3) of the Federal Food, Drug, and Cosmetic Act Guidance for Industry, 2011. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/postmarketing-studies-and-clinical-trials-implementation-section-505o3-federal-food-drug-and"},{"key":"e_1_3_7_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00357-1"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.24.00100","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T17:59:50Z","timestamp":1731693590000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.24.00100"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,20]]},"references-count":29,"journal-issue":{"issue":"33","published-print":{"date-parts":[[2024,11,20]]}},"alternative-id":["10.1200\/JCO.24.00100"],"URL":"https:\/\/doi.org\/10.1200\/jco.24.00100","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,20]]},"assertion":[{"value":"2024-01-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-21","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}